What is HC Wainwright’s Forecast for Zymeworks Q3 Earnings?

Zymeworks Inc. (NASDAQ:ZYME) – Equities researchers at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for shares of Zymeworks in a report released on Wednesday, August 5th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of $2.09 per share for the quarter, down from their previous forecast of $2.17. HC Wainwright currently has a “Buy” rating and a $51.00 price target on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.36 per share.

Zymeworks (NASDAQ:ZYME) last announced its earnings results on Tuesday, March 31st. The company reported ($0.59) EPS for the quarter. The company had revenue of $2.41 million for the quarter. Zymeworks had a negative net margin of 126.92% and a negative return on equity of 37.97%.

A number of other analysts have also commented on ZYME. Truist Financial increased their price objective on Zymeworks from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Citigroup reissued a “buy” rating on shares of Zymeworks in a research note on Tuesday, June 30th. Wells Fargo & Company upped their target price on shares of Zymeworks from $34.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.89.

Zymeworks Stock Up 3.1%

NASDAQ ZYME opened at $23.50 on Thursday. Zymeworks has a fifty-two week low of $11.51 and a fifty-two week high of $29.75. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -17.15 and a beta of 1.15. The business has a fifty day moving average of $24.07 and a 200-day moving average of $24.46.

Zymeworks declared that its board has approved a share buyback plan on Thursday, May 14th that authorizes the company to buyback $125.00 million in shares. This buyback authorization authorizes the company to reacquire up to 7% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its stock is undervalued.

Institutional Investors Weigh In On Zymeworks

Several hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC increased its stake in Zymeworks by 86.0% in the first quarter. AQR Capital Management LLC now owns 48,485 shares of the company’s stock valued at $577,000 after purchasing an additional 22,411 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Zymeworks by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company’s stock worth $386,000 after buying an additional 1,427 shares during the last quarter. Jane Street Group LLC boosted its stake in Zymeworks by 487.0% in the 1st quarter. Jane Street Group LLC now owns 135,763 shares of the company’s stock worth $1,617,000 after buying an additional 112,636 shares during the last quarter. Creative Planning grew its holdings in Zymeworks by 114.8% in the 2nd quarter. Creative Planning now owns 25,389 shares of the company’s stock valued at $319,000 after buying an additional 13,567 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Zymeworks by 1,050.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 441,690 shares of the company’s stock valued at $5,543,000 after buying an additional 403,281 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.